Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 2,840,667 |
|
|||||
| News | - | ||||||
| Day High | 14.005 | Low High |
|||||
| Day Low | 13.41 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| TG Therapeutics Inc | TGTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.34 | -2.44% | 13.57 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 13.94 | 13.41 | 14.005 | 13.47 | 13.91 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 22,160 | 2,840,667 | US$ 13.62 | US$ 38,702,983 | - | 6.46 - 35.67 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:59:37 | 1 | US$ 13.55 | USD |
TG Therapeutics (TGTX) Options Flow Summary
TG Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.08B | 154.42M | - | 233.66M | 12.67M | 0.08 | 164.19 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
TG Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TGTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 13.87 | 14.565 | 13.26 | 13.99 | 3,149,276 | -0.30 | -2.16% |
| 1 Month | 15.13 | 15.37 | 13.26 | 14.28 | 2,707,764 | -1.56 | -10.31% |
| 3 Months | 16.50 | 19.0175 | 12.84 | 15.29 | 3,455,938 | -2.93 | -17.76% |
| 6 Months | 7.07 | 22.67 | 6.89 | 14.54 | 4,986,556 | 6.50 | 91.94% |
| 1 Year | 22.33 | 35.67 | 6.46 | 15.85 | 4,781,926 | -8.76 | -39.23% |
| 3 Years | 42.86 | 45.50 | 3.48 | 14.62 | 3,465,399 | -29.29 | -68.34% |
| 5 Years | 8.09 | 56.74 | 3.48 | 16.34 | 2,769,683 | 5.48 | 67.74% |
TG Therapeutics Description
| TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. |
